A Phase IB Study of Onartuzumab Given with Sorafenib in Patients with Advanced Liver Cancer

Full Title
A Phase Ib, Open-Label Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Onartuzumab Given as a Single Agent and in Combination with Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC)

Onartuzumab is an investigational drug designed to inhibit cancer growth by blocking a protein on liver cancer cells called the MET antigen. It has been shown in laboratory studies to prevent or slow the growth of human cancer cells. It is given intravenously (by vein)

Sorafenib is a drug used to treat hepatocellular carcinoma (liver cancer). It works by inhibiting the development of the blood vessels that cancer cells need to grow and spread. It is a pill that is taken orally (by mouth). Despite sorafenib treatment, however, many patients with metastatic liver cancer experience continued tumor growth.

In this study, researchers are trying to find the highest dose of onartuzumab that can be given safely with or without sorafenib in patients with advanced liver cancer that has spread or has not responded to other treatment. It is hoped that the combination of these two drugs will be more effective than giving them alone.


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have advanced hepatocellular carcinoma.
  • Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
  • This study is open to patients age 18 and older.

For more information and to inquire about eligibility for this study, please contact Dr. Ghassan Abou-Alfa at 646-888-4184.

Hepatobiliary: Liver Cancer
Related Diseases